Exhibitor Tutorial

Round Table Discussions: Evaluation and Adoption of Advanced in-vitro Cancer Models for Drug Discovery & Development

Monday, February 5
12:30 PM - 2:30 PM
Location: Room 3

Sponsored by Lonza Bioscience

Our panel experts will share strategies and lessons-learned when evaluating in-vitro organ systems and
advanced cancer models. Presentations will be followed by round table discussions on current trends,
needs and barriers when adopting new technologies. The session will close with a panelist discussion
of breakout session ideas and potential follow-up actions to better support researchers in this rapidly
changing space.

To participate in these round table discussions or for more information, please contact Scott D’Andrea at scott.dandrea@lonza.com.


Round Table Panelist and Presenter
Tarig Magdeldin, Ph.D.
Postdoctoral Associate
Weill Cornell Medicine

“Engineering Biomimetic Models of Cancer”


Round Table Panelist and Presenter
Shane R. Horman, Ph.D.
Research Investigator III
GNF-Novartis

“In Vitro Cellular Platforms for Immuno-oncology Initiatives”

Round Table Panelist and Presenter
Madhu Lal Nag, Ph.D.
Head. Trans NIH RNAi Facility
NCATS/NIH

“Breaking Bad with 3D: The Development of High Throughput Screening Platforms to Interrogate Physiologically Relevant Models”

Moderator, Round Table Panelist and Presenter
Kristin Fabre, Ph.D.
Microphysiological Systems Development & Implementation Lead
AstraZeneca

“Building a Microphysiological System Implementation Strategy for AstraZeneca Research Projects”

ViewAttendees 9

Scott D'Andrea

Presentation(s):

ViewAttendees 9

Send Email for Scott D'Andrea

Tarig Magdeldin

Postdoctoral Associate
Weill Cornell Medicine

Cornell Medicine in New York focusing on engineering the blood brain barrier for cerebral organoids. Prior to that, Dr. Magdeldin earned his BSc in Cell and Molecular Biology from University College Dublin and his MSc and PhD from University College London (UCL) in Cancer Bioengineering. During his time at UCL in the laboratory of Dr. Umber Cheema, he developed complex 3D in vitro tumor models focusing specifically on how extracellular matrix density promotes cancer progression and angiogenesis.

Presentation(s):

ViewAttendees 9

Send Email for Tarig Magdeldin

Shane Horman

Research Investigator III
GNF

Dr. Shane Horman runs the Advanced Assay group at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. He received his Ph.D. from King’s College-London in molecular genetics and was a postdoc at the University of Pennsylvania-School of Medicine and then at Cincinnati Children’s Hospital Medical Center investigating mouse models of human leukemias. Dr. Horman’s Advanced Assay group at GNF is dedicated to the development and implementation of complex and 3D high content screening platforms that may better reflect in vivo patient biology for early stage drug discovery. Dr. Horman has published numerous papers on high content 3D screening platforms and regularly presents at phenotypic drug discovery conferences.

Presentation(s):

ViewAttendees 9

Send Email for Shane Horman

Madhu Lal Nag

Head. Trans NIH RNAi Facility
NCATS/NIH

Dr. Madhu Lal-Nag currently serves as the head of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS) which is responsible for developing and conducting genome wide physiologically relevant phenotypic assays for Intramural researchers. Madhu joined NCATS in 2013, where she worked as a research scientist primarily to develop an assay platform of 3 Dimensional physiologically relevant, multi-cell-type disease models that are amenable to high-throughput screening. She has extensive experience in the miniaturization and optimization of physiologically relevant cell-based 2D and 3D assays to make them amenable for the screening of high-impact small molecule and functional genomics libraries with the goal of identifying unique receptor/ligand interaction and efficacy in various disease pathologies especially as they relate to the epigenetic modulation of cancer and stem cell biology.

Presentation(s):

ViewAttendees 9

Send Email for Madhu Lal Nag

Kristin Fabre

Microphysiological Systems Development & Implementation Lead
AstraZeneca

Dr. Kristin Fabre is the Microphysiological Systems Development and Implementation Lead at AstraZeneca, working with several key partners to develop how to best utilize MPS technology for drug development. Prior to joining AZ, she was the Scientific Program Manager for the Microphysiological Systems (or Organs-on-Chips) Initiative at NIH National Center for Advancing Translational Sciences (NCATS).

Presentation(s):

ViewAttendees 9

Send Email for Kristin Fabre


Assets

Round Table Discussions: Evaluation and Adoption of Advanced in-vitro Cancer Models for Drug Discovery & Development



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Round Table Discussions: Evaluation and Adoption of Advanced in-vitro Cancer Models for Drug Discovery & Development